A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and Seasonal Inactivated Influenza Vaccine in PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, sponsored by Pfizer. Completed at 44 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-01.
Sponsored by Pfizer · Phase 4, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.
Among the 15 studies in Influenza, Human by Pfizer, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 4, and was the 2nd registered.
2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.
Browse Influenza, Human studies →1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 882 is above the median of 227 across 1,957 interventional studies indexed under Influenza, Human.
Median enrollment 882 across the 11 interventional studies, 5,075 across the 4 observational. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Influenza, Human by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05160636PfizerA Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza | 2027-01-31 |
| NCT07431853PfizerA Study to Learn About mRNA Vaccines Against Influenza in Adults | 2027-06-22 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Influenza, Human by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have previously received 23-valent pneumococcal polysaccharide vaccine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: 13-valent pneumococcal conjugate vaccine · Biological: Seasonal Inactivated Influenza Vaccine · Other: Placebo
Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine · Biological: 13-valent pneumococcal conjugate vaccine
One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
Also known as: 13vPnC
One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
Also known as: SIIV
One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
Also known as: SIIV
One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
Also known as: 13vPnC
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes
Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with a determinate OPA titer to the given serotype.
Time frame: 1 month after Vaccination 1 for 13vPnC+QIV/Placebo, 1 Month After Vaccination 2 for Placebo+QIV/13vPnC
Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)
HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies participants with a determinate HAI titer to the given strain.
Time frame: 1 month after Vaccination 1
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
Time frame: Within 28 to 42 days after Vaccination 1
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
Time frame: Within 28 to 42 days after Vaccination 2
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
Time frame: Baseline (Vaccination 1) up to 28 to 42 Days after Vaccination 2
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
Time frame: Within 168 to 196 days after Vaccination 2
Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)
Percentage of participants achieving predefined OPA antibody titer \>= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results to the specified serotype.
Time frame: 1 Month After Vaccination 1 for 13vPnC+QIV/Placebo, 1 month after Vaccination 2 for Placebo+QIV/13vPnC
Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.
Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1
Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, "number of participants analyzed" signifies total participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.
Time frame: Immediately before Vaccination 2, 1 month after Vaccination 2
Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers
Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than \<1:10 and after Vaccination 1 (post-vaccination 1) HAI titer \>=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer \>=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint.
Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1
Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1
Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, "number of participants analyzed" signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.
Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1
| Milestone | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Started | 441 | 441 |
| Vaccination 1 | 439 | 437 |
| Vaccination 2 | 431 | 432 |
| Completed | 425 | 426 |
| Not completed | 16 | 15 |
| Withdrew: Other unspecified | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Does not meet entrance criteria | 2 | 3 |
| Withdrew: No longer meets eligibility criteria | 5 | 4 |
| Withdrew: Lost to follow-up | 3 | 4 |
Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with a determinate OPA titer to the given serotype.
| titer | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Serotype 1 (n= 419, 417) | 75 (65.0 to 87.0) | 83 (71.1 to 96.1) |
| Serotype 3 (n= 422, 418) | 41 (36.2 to 46) | 49 (43.6 to 55.3) |
| Serotype 4 (n= 412, 417) | 587 (489.9 to 702.5) | 824 (692.2 to 980) |
| Serotype 5 (n= 423, 414) | 97 (83.8 to 111.7) | 101 (86.6 to 117.2) |
| Serotype 6A (n= 420, 415) | 953 (805.7 to 1126.3) | 1413 (1203.3 to 1659.4) |
| Serotype 6B (n= 414, 405) | 867 (722.3 to 1039.6) | 1041 (860.5 to 1260) |
| Serotype 7F (n= 424, 419) | 651 (582.4 to 728) | 670 (599.7 to 748.5) |
| Serotype 9V (n= 419, 415) | 699 (613.7 to 797.2) | 838 (734.2 to 957.5) |
| Serotype 14 (n= 421, 416) | 574 (496.8 to 663) | 760 (665.6 to 868) |
| Serotype 18C (n= 420, 414) | 713 (598.9 to 849.9) | 865 (726.4 to 1030.5) |
| Serotype 19A (n= 425, 419) | 337 (294.9 to 384.6) | 390 (344.4 to 441.1) |
| Serotype 19F (n= 423, 416) | 324 (274.8 to 382.5) | 360 (302.7 to 427.9) |
| Serotype 23F (n= 421, 417) | 278 (223.9 to 344.7) | 364 (294.3 to 451.3) |
HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies participants with a determinate HAI titer to the given strain.
| titer | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Strain: A/H1N1 | 115 (104.0 to 126.8) | 113 (101.6 to 124.7) |
| Strain: A/H3N2 | 226 (206.1 to 248.5) | 196 (178.0 to 216.1) |
| Strain: B/Brisbane | 28 (25.7 to 31.0) | 26 (23.7 to 28.7) |
| Strain: B/Massachusetts | 45 (41.0 to 50.3) | 43 (39.1 to 48.2) |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| AE | 15.3 | 11.9 |
| SAE | 1.4 | 0 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| AE | 10.4 | 12.5 |
| SAE | 1.6 | 1.4 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| AE | 15.3 | 12.5 |
| SAE | 1.4 | 1.4 |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| AE | 2.5 | 2.7 |
| SAE | 1.1 | 1.4 |
Percentage of participants achieving predefined OPA antibody titer \>= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results to the specified serotype.
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Serotype 1 (n= 419, 417) | 77.3 (73.0 to 81.3) | 80.1 (75.9 to 83.8) |
| Serotype 3 (n= 422, 418) | 79.4 (75.2 to 83.1) | 83.7 (79.8 to 87.1) |
| Serotype 4 (n= 412, 417) | 88.6 (85.1 to 91.5) | 92.1 (89.1 to 94.5) |
| Serotype 5 (n= 423, 414) | 74.5 (70.0 to 78.6) | 72.7 (68.1 to 76.9) |
| Serotype 6A (n= 420, 415) | 90.5 (87.3 to 93.1) | 94.2 (91.5 to 96.3) |
| Serotype 6B (n= 414, 405) | 85.0 (81.2 to 88.3) | 86.4 (82.7 to 89.6) |
| Serotype 7F (n= 424, 419) | 82.3 (78.3 to 85.8) | 83.5 (79.6 to 87.0) |
| Serotype 9V (n= 419, 415) | 65.2 (60.4 to 69.7) | 71.3 (66.7 to 75.6) |
| Serotype 14 (n= 421, 416) | 91.4 (88.4 to 93.9) | 95.2 (92.7 to 97.0) |
| Serotype 18C (n= 420, 414) | 88.8 (85.4 to 91.7) | 91.3 (88.2 to 93.8) |
| Serotype 19A (n= 425, 419) | 95.5 (93.1 to 97.3) | 97.4 (95.4 to 98.7) |
| Serotype 19F (n= 423, 416) | 79.9 (75.8 to 83.6) | 79.6 (75.4 to 83.3) |
| Serotype 23F (n= 421, 417) | 80.3 (76.2 to 84.0) | 84.2 (80.3 to 87.5) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.
| fold rise | 13vPnC+QIV/Placebo |
|---|---|
| Serotype 1 (n= 417) | 3.6 (3.20 to 4.14) |
| Serotype 3 (n= 419) | 3.4 (3.05 to 3.85) |
| Serotype 4 (n= 399) | 9.1 (7.33 to 11.18) |
| Serotype 5 (n= 422) | 3.0 (2.70 to 3.43) |
| Serotype 6A (n= 408) | 13.7 (11.30 to 16.62) |
| Serotype 6B (n= 391) | 8.9 (7.29 to 10.87) |
| Serotype 7F (n= 417) | 2.7 (2.40 to 2.98) |
| Serotype 9V (n= 405) | 2.1 (1.92 to 2.38) |
| Serotype 14 (n= 411) | 2.0 (1.78 to 2.30) |
| Serotype 18C (n= 417) | 4.0 (3.38 to 4.74) |
| Serotype 19A (n= 424) | 3.7 (3.20 to 4.28) |
| Serotype 19F (n= 419) | 4.2 (3.60 to 4.87) |
| Serotype 23F (n= 418) | 8.7 (7.07 to 10.61) |
GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, "number of participants analyzed" signifies total participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.
| fold rise | Placebo+QIV/13vPnC |
|---|---|
| Serotype 1 (n =413) | 3.6 (3.19 to 4.16) |
| Serotype 3 (n= 414) | 3.9 (3.47 to 4.42) |
| Serotype 4 (n= 391) | 10.4 (8.28 to 12.94) |
| Serotype 5 (n= 411) | 3.3 (2.87 to 3.72) |
| Serotype 6A (n= 399) | 17.9 (14.73 to 21.86) |
| Serotype 6B (n= 382) | 9.5 (7.69 to 11.67) |
| Serotype 7F (n= 407) | 2.7 (2.41 to 3.03) |
| Serotype 9V (n= 399) | 2.4 (2.12 to 2.71) |
| Serotype 14 (n= 406) | 2.3 (1.98 to 2.60) |
| Serotype 18C (n= 408) | 6.3 (5.21 to 7.51) |
| Serotype 19A (n= 416) | 4.6 (4.02 to 5.35) |
| Serotype 19F (n= 410) | 4.8 (4.12 to 5.69) |
| Serotype 23F (n= 412) | 12.9 (10.42 to 15.88) |
Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than \<1:10 and after Vaccination 1 (post-vaccination 1) HAI titer \>=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer \>=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint.
| percentage of participants | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Strain: A/H1N1 | 29.3 (25.0 to 33.8) | 24.2 (20.2 to 28.5) |
| Strain: A/H3N2 | 27.9 (23.7 to 32.4) | 31.6 (27.3 to 36.3) |
| Strain: B/Brisbane | 21.3 (17.5 to 25.5) | 22.3 (18.5 to 26.6) |
| Strain: B/Massachusetts | 23.2 (19.3 to 27.5) | 24.7 (20.6 to 29.0) |
Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, "number of participants analyzed" signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.
| fold rise | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC |
|---|---|---|
| Strain: A/H1N1 | 2.4 (2.17 to 2.64) | 2.2 (2.01 to 2.41) |
| Strain: A/H3N2 | 2.3 (2.09 to 2.51) | 2.4 (2.15 to 2.59) |
| Strain: B/Brisbane | 2.1 (1.97 to 2.32) | 2.2 (1.98 to 2.34) |
| Strain: B/Massachusetts | 2.2 (1.98 to 2.34) | 2.1 (1.98 to 2.30) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC+QIV/Placebo: After Vaccination 1 | — | 6/439 (1.4%) | 62/439 (14.1%) |
| Placebo+QIV/13vPnC: After Vaccination 1 | — | 0/437 (0%) | 52/437 (11.9%) |
| 13vPnC+QIV/Placebo: After Vaccination 2 | — | 7/431 (1.6%) | 42/431 (9.7%) |
| Placebo+QIV/13vPnC: After Vaccination 2 | — | 6/432 (1.4%) | 51/432 (11.8%) |
| 13vPnC+QIV/Placebo: After 13vPnC Vaccination | — | 6/439 (1.4%) | 62/439 (14.1%) |
| Placebo+QIV/13vPnC: After 13vPnC Vaccination | — | 6/432 (1.4%) | 51/432 (11.8%) |
| 13vPnC+QIV/Placebo: at 6-Month Follow-up | — | 5/439 (1.1%) | 6/439 (1.4%) |
| Placebo+QIV/13vPnC: at 6-Month Follow-up | — | 6/437 (1.4%) | 6/437 (1.4%) |
| Event | 13vPnC+QIV/Placebo: After Vaccination 1 | Placebo+QIV/13vPnC: After Vaccination 1 | 13vPnC+QIV/Placebo: After Vaccination 2 | Placebo+QIV/13vPnC: After Vaccination 2 | 13vPnC+QIV/Placebo: After 13vPnC Vaccination | Placebo+QIV/13vPnC: After 13vPnC Vaccination | 13vPnC+QIV/Placebo: at 6-Month Follow-up | Placebo+QIV/13vPnC: at 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/439 | 0/437 | 2/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| PneumoniaInfections and infestations | 0/439 | 0/437 | 0/431 | 0/432 | 0/439 | 0/432 | 0/439 | 2/437 |
| CellulitisInfections and infestations | 1/439 | 0/437 | 1/431 | 0/432 | 1/439 | 0/432 | 0/439 | 0/437 |
| Cardiogenic shockCardiac disorders | 0/439 | 0/437 | 1/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| DyspepsiaGastrointestinal disorders | 0/439 | 0/437 | 1/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| VomitingGastrointestinal disorders | 0/439 | 0/437 | 1/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| OsteomyelitisInfections and infestations | 0/439 | 0/437 | 1/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/439 | 0/437 | 1/431 | 0/432 | 0/439 | 0/432 | 0/439 | 0/437 |
| Cardiac failure congestiveCardiac disorders | 0/439 | 0/437 | 0/431 | 1/432 | 0/439 | 1/432 | 0/439 | 0/437 |
| Coronary artery diseaseCardiac disorders | 0/439 | 0/437 | 0/431 | 1/432 | 0/439 | 1/432 | 0/439 | 0/437 |
| Event | 13vPnC+QIV/Placebo: After Vaccination 1 | Placebo+QIV/13vPnC: After Vaccination 1 | 13vPnC+QIV/Placebo: After Vaccination 2 | Placebo+QIV/13vPnC: After Vaccination 2 | 13vPnC+QIV/Placebo: After 13vPnC Vaccination | Placebo+QIV/13vPnC: After 13vPnC Vaccination | 13vPnC+QIV/Placebo: at 6-Month Follow-up | Placebo+QIV/13vPnC: at 6-Month Follow-up |
|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 8/439 | 2/437 | 0/431 | 3/432 | 8/439 | 3/432 | 0/439 | 0/437 |
| Upper respiratory tract infectionInfections and infestations | 8/439 | 4/437 | 3/431 | 4/432 | 8/439 | 4/432 | 0/439 | 0/437 |
| Urinary tract infectionInfections and infestations | 5/439 | 1/437 | 2/431 | 4/432 | 5/439 | 4/432 | 0/439 | 0/437 |
| BronchitisInfections and infestations | 3/439 | 4/437 | 4/431 | 4/432 | 3/439 | 4/432 | 0/439 | 0/437 |
| NasopharyngitisInfections and infestations | 3/439 | 3/437 | 4/431 | 1/432 | 3/439 | 1/432 | 0/439 | 0/437 |
| FallInjury, poisoning and procedural complications | 0/439 | 1/437 | 4/431 | 2/432 | 0/439 | 2/432 | 1/439 | 0/437 |
| HeadacheNervous system disorders | 0/439 | 3/437 | 4/431 | 2/432 | 0/439 | 2/432 | 0/439 | 0/437 |
| SinusitisInfections and infestations | 2/439 | 2/437 | 1/431 | 4/432 | 2/439 | 4/432 | 0/439 | 0/437 |
| PyrexiaGeneral disorders | 0/439 | 4/437 | 0/431 | 1/432 | 0/439 | 1/432 | 0/439 | 0/437 |
| NauseaGastrointestinal disorders | 0/439 | 1/437 | 3/431 | 3/432 | 0/439 | 3/432 | 0/439 | 0/437 |
Safety population included all participants who received at least 1 dose of vaccination.
| Age, Continuous(years) | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC | Total |
|---|---|---|---|
| Mean | 66.9 ± 9 | 66.4 ± 8.85 | 66.7 ± 8.93 |
| Sex: Female, Male(Participants) | 13vPnC+QIV/Placebo | Placebo+QIV/13vPnC | Total |
|---|---|---|---|
| Female | 234 | 249 | 483 |
| Male | 205 | 188 | 393 |
The record gives a start of Sep 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine